Drug Profile
Research programme: peginterferon lambda - Ambrx
Alternative Names: PEG-INF lambda - Ambrx; Pegylated interferon lambda - AmbrxLatest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ambrx
- Class Interferons
- Mechanism of Action Interleukin 29 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (Parenteral)
- 21 May 2013 Preclinical trials in Hepatitis C in USA (Parenteral)